



Applicants : Simons *et al.* Serial No. : 09/145,916

Filed : September 2, 1998

For : "STIMULATION OF ANGIOGENESIS VIA ENHANCED

ENDOTHELIAL EXPRESSION OF SYNDECAN-4

CORE PROTEINS"

Examiner : David Guzo

Group Art Unit : 1636 Attorney's Docket No. : BIS-039

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on: 19, 2004.

Attorney for applicants: \(\sigma_{av} \)

Signature:

Date

July 19, 2004

THIRD STATEMENT AND VERIFICATION OF SUBSTANTIVE IDENTITY BETWEEN THE THIRD COMPUTER READABLE FORM (CRF) COPY

AND THE THIRD PAPER FORM COPY OF THE "SEQUENCE LISTING"

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

In substantive response to the Notice To Comply With Requirements

For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid

Sequence Disclosures mailed April 20, 2004 and extended through July 20, 2004, applicants' undersigned attorney states and verifies the following:

The content of the third paper form copy and the third computer readable form (CRF) copy of the "Sequence Listing" enclosed herewith are the same; the content of the third paper form copy and the third computer readable form (CRF) copy of the "Sequence Listings" enclosed herewith do not contain any New Matter; and the content of the third paper form copy and the third computer readable form (CRF) copy of the "Sequence Listing" enclosed herewith is fully supported by the descriptive and enabled disclosure of the Specification text originally filed September 2, 1998 as USSN 09/145,916.

This third statement and verification of the contents and sameness of the "Sequence Listing" in third paper form copy and third computer readable form (CRF) copy is made pursuant to and in compliance with the requirements as set forth in 37 C.F.R. 1.821-1.825 respectively. Applicants' undersigned attorney respectfully submits that this third statement and verification is also a legally complete and sufficient Response to the instant Notice to comply with requirements for sequence disclosures as such.

Respectfully submitted,

MICHAEL SIMONS **RUDIGER VOLK** ARIE HOROWITZ

Date: 14, 2004
P.O. Box 5380
Magnolia, Massachusetts 01930
Tel.: (978) 525-3794

David Prashker Reg. No. 29,693 Attorney for applicants

BEST AVAILABLE COPY

Application No.

SOTTCE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 -1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821
- 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29 May 15, 1990 and at 55 FR 18230, May 1, 1990.
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted.
However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been
found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer
readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
7. Other:————————————————————————————————————
Applicant must provide:
An initial on substitute computer woodsble form (SRE) compute the "Somuces

substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123

For CRF submission help, call (703) 308-4212

For PatentIn software help, call (703) 557-0400